Skip to content

MV Lifesciences

Active Private limited companyfounded 2022active for 4 yearsRue de Genval 22, 1331 RixensartKBO/BCE: BE 0781.705.776

Lifetime

4 annual accounts with figures on one time axis
peak of €213,161 in 2023
€196,382▼ 5.2%
peak of €160,603 in 2023
€155,021▲ 3.1%
peak of €256,134 in 2024
€146,155▼ 42.9%
€349,464▲ 340%
Board1 name since 2022
1 director
Documentsfilings and deeds
21-08-202621 days late
2025micro format
Dividend €265,000Equity from €256,134 to €146,155Debts from €79,371 to €349,464

Key points

from the 2025 annual accounts

Equity

€146,155 ▼ 42.9%
256,1342024+155,021Profit-265,000Dividend146,1552025

MV Lifesciences paid out €265,000 in dividends. That is 171% of the 2025 profit.

Turnover

≈ €300,000 estimated

The micro format states no turnover.

Debts

€349,464 71% of the balance sheet
Suppliers 1%Taxes and wages 38%Other 61%

Liquidity

1.21 was 3.29 in 2024

Short-term debts rose from €79,371 to €349,464.

Filings

4 annual accounts 3 late
AprilJune31 JulyOctober2022202320242025

The 2025 accounts came in latest, 21 days after the end of the period.

Position in the sector

€155,021

Higher net result than 95% of companies in office administrative support. The sector median is €15,202, over 10,299 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,603 companies had the same profile as MV Lifesciences has now. Each dot stands for 5 companies, two years later.

96.3%
were still trading
1.2%
stopped another way
2.4%
went bankrupt
  • Small
  • 2 to 5 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,603 companies, not a prediction for MV Lifesciences. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 200 sharesdeed of 10-02-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0781705776
Incorporation Founding capital of €20,000, 200 shares · Founded by · appointed as director · published on 10-02-2022 · Gazette deed
First establishment Rue de Genval 22, Rixensart
All 11 events

Comparable companies

same main activity, similar in size and age
Company
MV Lifesciences Rixensart €495,619 €196,382 29.5% -
Marineau Brasschaat €497,596 €201,595 85.9% -
Biocheck.Gent Dentergem €478,660 €216,100 61.6% -
LINDEBOS Hasselt €449,697 €182,578 -2.5% -
LATULE Brasschaat €528,603 €211,998 95.3% -
CVH & Co Consulting Dilbeek €555,580 €200,712 84.9% -
GIELEN RUBEN Oudsbergen €571,908 €197,215 55.5% -

These companies have the same main activity as MV Lifesciences: other business support services (NACE 82990). They are comparable in size and age: total assets between €450,000 and €572,000, founded between 2021 and 2022.

Official details

Source: KBO
Status
Active since 08-02-2022Normal situation
Activity
Other business support servicesNACE 82990and 4 others
Establishment unit
2.328.085.3201331 Rixensart, since 08-02-2022
Financial year end
31 December
Peppol
Reachable since 05-05-2025
Company details

Annual accounts 2025

€495,619▲ 47.7%
Filing
Filed on 21-08-2026
Financials

Insights on MV Lifesciences

MV Lifesciences files the micro format. That format states no turnover. The gross margin fell from €199,168 in 2022 to €196,382 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MV Lifesciences

What is the company number of MV Lifesciences?
The company number of MV Lifesciences is 0781.705.776. The VAT number is the same number with BE in front: BE 0781.705.776.
Where is MV Lifesciences based?
The registered office is at Rue de Genval 22, 1331 Rixensart.Company details
What does MV Lifesciences do?
According to the KBO register, the main activity is other business support services (NACE 82990).
What is the legal form of MV Lifesciences?
MV Lifesciences is a private limited company (BV).
When was MV Lifesciences founded?
MV Lifesciences was founded on 08-02-2022.
Is MV Lifesciences still active?
Yes, MV Lifesciences is an active enterprise in the KBO register.
What is the turnover of MV Lifesciences?
The turnover in financial year 2025 is about €300,000. This figure is estimated from the gross margin of €196,382 and 31 comparable companies (NACE 82990). It probably lies between €230,000 and €410,000.Financials
Is MV Lifesciences profitable?
In financial year 2025, MV Lifesciences made a profit of €155,021.
Where can I find the annual accounts of MV Lifesciences?
MV Lifesciences filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MV Lifesciences due?
MV Lifesciences must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.